Falsified batches of the cancer medicine Herceptin® from Roche have been identified in England, Germany and Finland. None of the affected batches have been distributed in Denmark.
Treatment for breast cancer patients
In Denmark, Herceptin® is only used in hospitals and mainly to treat patients with breast cancer.
Herceptin® contains the active substance trastuzumab. Only the 150 mg strength has been falsified.
Read the EMA’s press release of 16 April 2014
On 17 April 2014, EMA issued an update to the press release on falsified batches of Herceptin®.
The Danish Health and Medicines Authority has examined the additional products mentioned in the EMA’s update and has found that none of the products are distributed in the Danish market.